Kobach announces $720 million opioid settlement with drug manufacturers

TOPEKA – (July 14, 2025) - Kansas Attorney General Kris Kobach today announced an approximate $720 million nationwide settlement with eight drug makers that manufactured opioid pills and worsened the nationwide opioid crisis. Kansas stands to receive approximately $5.7 million in settlement funds.
 
“We are holding these companies accountable for the human suffering caused by years of their illegal marketing practices,” Kobach said. “These dollars will help save lives, because the funds will be used to prevent and treat drug addiction throughout Kansas."
 
The eight defendants and the total amount they will pay in funds to address the opioid crisis as part of the deal are:

• Mylan (now part of Viatris): $284,447,916 paid over nine years 
• Hikma: $95,818,293 paid over one to four years 
• Amneal: $71,751,010 paid over 10 years 
• Apotex: $63,682,369 paid in a single year 
• Indivior: $38,022,450 paid over four years 
• Sun: $30,992,087 paid over one to four years 
• Alvogen: $18,680,162 paid in a single year 
• Zydus: $14,859,220 paid in a single year 

 
In addition to these abatement payments, several of the settlements allow states to receive free pharmaceutical products or cash in lieu of this product.  Additionally, seven of the companies (not including Indivior) are prohibited from promoting or marketing opioids and opioid products, making or selling any product that contains more than 40 mg of oxycodone per pill, and are required to put in place a monitoring and reporting system for suspicious orders. Indivior has agreed to not manufacture or sell opioid products for the next 10 years, but it will be able to continue marketing and selling medications to treat opioid use disorder.  
 
North Carolina, California, Colorado, Illinois, New York, Oregon, Tennessee, Utah, and Virginia attorneys general offices negotiated the settlements on behalf of Kansas and several other states.